WO2022058617A1 - Tissu cardiaque particulier et utilisation dans le traitement de pathologies cardiaque - Google Patents
Tissu cardiaque particulier et utilisation dans le traitement de pathologies cardiaque Download PDFInfo
- Publication number
- WO2022058617A1 WO2022058617A1 PCT/EP2021/075951 EP2021075951W WO2022058617A1 WO 2022058617 A1 WO2022058617 A1 WO 2022058617A1 EP 2021075951 W EP2021075951 W EP 2021075951W WO 2022058617 A1 WO2022058617 A1 WO 2022058617A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cardiac
- tissue
- compacted
- human
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title claims abstract description 82
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 230000007170 pathology Effects 0.000 title claims abstract description 11
- 210000005003 heart tissue Anatomy 0.000 title description 86
- 210000002064 heart cell Anatomy 0.000 claims abstract description 101
- 108090000362 Lymphotoxin-beta Proteins 0.000 claims abstract description 27
- 102000013534 Troponin C Human genes 0.000 claims abstract description 26
- 230000002269 spontaneous effect Effects 0.000 claims abstract description 19
- 230000008602 contraction Effects 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 188
- 230000004069 differentiation Effects 0.000 claims description 109
- 238000000034 method Methods 0.000 claims description 66
- 239000000017 hydrogel Substances 0.000 claims description 58
- 210000005260 human cell Anatomy 0.000 claims description 39
- 210000002216 heart Anatomy 0.000 claims description 38
- 230000008569 process Effects 0.000 claims description 34
- 239000007864 aqueous solution Substances 0.000 claims description 33
- 238000005056 compaction Methods 0.000 claims description 13
- 108010063503 Actinin Proteins 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 102000010825 Actinin Human genes 0.000 claims description 10
- 238000010494 dissociation reaction Methods 0.000 claims description 10
- 230000005593 dissociations Effects 0.000 claims description 10
- 239000004744 fabric Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 208000019622 heart disease Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000008034 disappearance Effects 0.000 claims description 4
- 229940000406 drug candidate Drugs 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000020446 Cardiac disease Diseases 0.000 claims description 2
- 206010048610 Cardiotoxicity Diseases 0.000 claims description 2
- 231100000259 cardiotoxicity Toxicity 0.000 claims description 2
- 230000007681 cardiovascular toxicity Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 description 114
- 210000000130 stem cell Anatomy 0.000 description 42
- 210000004413 cardiac myocyte Anatomy 0.000 description 41
- 239000002775 capsule Substances 0.000 description 40
- 230000001413 cellular effect Effects 0.000 description 27
- 238000005538 encapsulation Methods 0.000 description 27
- 210000001778 pluripotent stem cell Anatomy 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 239000001963 growth medium Substances 0.000 description 24
- 238000002135 phase contrast microscopy Methods 0.000 description 22
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 21
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 21
- 210000002744 extracellular matrix Anatomy 0.000 description 21
- 238000002513 implantation Methods 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 235000010443 alginic acid Nutrition 0.000 description 16
- 229920000615 alginic acid Polymers 0.000 description 16
- 102000013814 Wnt Human genes 0.000 description 15
- 108050003627 Wnt Proteins 0.000 description 15
- 230000024245 cell differentiation Effects 0.000 description 15
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 14
- -1 MESP-1 Proteins 0.000 description 14
- 229940072056 alginate Drugs 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 13
- 238000002659 cell therapy Methods 0.000 description 12
- 210000001671 embryonic stem cell Anatomy 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 10
- 230000035559 beat frequency Effects 0.000 description 9
- 206010003119 arrhythmia Diseases 0.000 description 8
- 230000006793 arrhythmia Effects 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 239000012979 RPMI medium Substances 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 6
- 101000713606 Homo sapiens T-box transcription factor TBX20 Proteins 0.000 description 6
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 6
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 6
- 102000055120 MEF2 Transcription Factors Human genes 0.000 description 6
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 6
- 108010014480 T-box transcription factor 5 Proteins 0.000 description 6
- 102100036833 T-box transcription factor TBX20 Human genes 0.000 description 6
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 230000008520 organization Effects 0.000 description 6
- 230000003076 paracrine Effects 0.000 description 6
- 239000012583 B-27 Supplement Substances 0.000 description 5
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 5
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 5
- 101150038994 PDGFRA gene Proteins 0.000 description 5
- 102100024755 T-box transcription factor TBX5 Human genes 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 101000685824 Homo sapiens Probable RNA polymerase II nuclear localization protein SLC7A6OS Proteins 0.000 description 4
- 101000801260 Homo sapiens Troponin C, slow skeletal and cardiac muscles Proteins 0.000 description 4
- 101000851334 Homo sapiens Troponin I, cardiac muscle Proteins 0.000 description 4
- 102100023136 Probable RNA polymerase II nuclear localization protein SLC7A6OS Human genes 0.000 description 4
- 102100033744 Troponin C, slow skeletal and cardiac muscles Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000003305 autocrine Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- ZGSXEXBYLJIOGF-BOPNQXPFSA-N iwr-1 Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2C(C=C3)CC3[C@@H]2C1=O ZGSXEXBYLJIOGF-BOPNQXPFSA-N 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000003716 mesoderm Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000003592 biomimetic effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940121396 wnt pathway inhibitor Drugs 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100037369 Nidogen-1 Human genes 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000017455 cell-cell adhesion Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001001 laser micro-dissection Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 108010008217 nidogen Proteins 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 2
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000009168 stem cell therapy Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100032964 Alpha-actinin-2 Human genes 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000410367 Clerodendrum thomsoniae Species 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000797275 Homo sapiens Alpha-actinin-2 Proteins 0.000 description 1
- 101000629402 Homo sapiens Mesoderm posterior protein 1 Proteins 0.000 description 1
- 102100026822 Mesoderm posterior protein 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 108700004892 gelatin methacryloyl Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
Definitions
- the invention relates to the treatment of cardiac diseases, in particular ischemic heart diseases, by the use of specific cardiac tissues obtained from particular cellular microcompartments comprising human cells expressing genes expressed during cardiac differentiation
- cardiovascular disease and in particular ischemic heart disease (which usually leads to myocardial infarction), is the leading cause of death worldwide (Thomas, H. et al. Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention and Control.Glob.Heart 13, 143-163 (2016)).
- hPSC-CMs human pluripotent stem cell-derived cardiomyocytes
- hPSC-CMs human pluripotent stem cell-derived cardiomyocytes
- hPSC-CMs human embryonic stem cells and induced pluripotent stem cells
- cardiomyocytes can be used for other applications, in particular as biological pacemakers for the treatment of node dysfunction.
- sinus (Lee, JH, Protze, SI, Laksman, Z., Backx, PH & Keller, GM Human Pluripotent Stem Cell-Derived Atrial and Ventricular Cardiomyocytes Develop from Distinct Mesoderm Populations. Cell Stem Cell 21, 179-194. e4 (2017 )), or to treat congenital heart disease, such as septal anomalies (Devalla, HD & Passier, R. Cardiac differentiation of pluripotent stem cells and implications for modeling the heart in health and disease. Sc/. Transi. Med.
- micro-supports still leave the cells exposed to mechanical stresses and which can be difficult to remove
- the object of the invention is therefore to meet all of these needs and to overcome the drawbacks and limitations of the prior art.
- the inventors have developed a particular heart tissue.
- the invention relates specifically to a compacted tissue of cardiac human cells expressing cardiac troponin C (that is to say human cells expressing the gene for cardiac troponin C, the alias of the corresponding gene being TNNC1), contractile and exhibiting a spontaneous contraction frequency of less than 4 Hz.
- cardiac troponin C that is to say human cells expressing the gene for cardiac troponin C, the alias of the corresponding gene being TNNC1
- a subject of the invention is also a compacted tissue of contractile human cardiac cells expressing cardiac troponin C (that is to say human cells expressing the gene for cardiac troponin C, the alias of the corresponding gene being TNNC1).
- the compacted tissue of human cardiac cells according to the invention has a rate of cells expressing cardiac troponin C of at least 50% in number relative to the total number of cells constituting the compacted tissue, even more preferably of at least 60 %, at least 70%, at least 75%, at least 80%, and this rate may be greater than 90%.
- the compacted tissue of human cardiac cells according to the invention has a level of cells expressing alpha-actinin of at least 50% in number relative to the total number of cells constituting the compacted tissue, even more preferably of at least least least 60%, at least 70%, at least 75%, at least 80%, and this rate may be greater than 90%.
- the compacted tissue of human cardiac cells according to the invention has a rate of cells expressing troponin C and alpha-actinin of at least 50% in number relative to the total number of cells constituting the compacted tissue, even more preferably at least 60%, at least 70%, at least 75%, at least 80%, and this rate may be greater than 90%.
- the cardiac tissues according to the invention obtained by a specific process different from those of the prior art, makes it possible to obtain cardiac tissues with a rate of cells expressing cardiac troponin C and/or alpha-actinin of at least 50%, and preferably at least 75%.
- the configuration according to the invention during differentiation allows the transmission of auto/paracrine signals within a protected lumen which allows the cells to self-organize in a biomimetic way of the in vivo structuring.
- This structuring is extremely fragile and requires both mechanical protection and available space, contrary to what is described in Koivisto Janne T. et al. According to the invention, this configuration cannot be implemented either in a confined system or in an unprotected system.
- the invention proposes a controlled structuring of the environment in the form of a self- protected organization, which allows less sensitivity to small variations in the cropping system and therefore greater reproducibility.
- these cardiac tissues are suitable for uses in cell therapy.
- these tissues can be used to regenerate ischemic heart tissue.
- the invention relates to said tissues, as such or after dissociation into cells, for their use in the prevention and/or treatment of pathologies, in particular cardiac pathologies.
- a key developmental intermediary namely a three-dimensional (3D) cellular microcompartment comprising successively, organized around at least one lumen:
- At least one inner layer of human cells in the process of cell differentiation into cardiac cells expressing at least one gene chosen from PDGFRa, MESP-1, NKX2-5, GATA4, MEF2C, TBX20, ISL1 and TBX5, said inner layer having a variable thickness;
- Such a microcompartment therefore comprises cells in the process of cell differentiation, the expression of the PDGFRa / MESP1 / NKX2-5 / GATA4 / MEF2C / TBX20 / ISL1 / TBX5 genes being associated with intermediate stages of cardiac differentiation.
- This configuration one or more lumens around which are successively organized a layer of human cells undergoing cardiac differentiation with specific thickness characteristics, a layer of isotonic aqueous solution and at least one hydrogel layer) is new.
- an outer layer of hydrogel and an intermediate layer of isotonic aqueous solution allows a uniform distribution of cells between the microcompartments.
- the homogeneity between the microcompartments is greatly improved by the prior encapsulation of the hPSCs allowing increased yield and quality compared to existing methods.
- this layer of hydrogel makes it possible to avoid fusions of microcompartments which are a major source of unfavorable variability for the phenotypic homogeneity and the survival of the cardiac cells produced in the bioreactor.
- modulation of the WNT pathway used in cardiac differentiation is associated with
- the topology of the microcompartment makes it possible to protect the cells in the process of cardiac differentiation, despite the fragility of the cell-cell adhesion induced by the modulation of the WNT pathway.
- Figure la is a schematic representation of a sectional view of a compacted cardiac tissue 22 according to the invention, corresponding to the photo shown in figure lb, with an outer layer of hydrogel 12, a layer of isotonic aqueous solution 14, a fabric packed with differentiated heart cells 20.
- Figure lb is a phase contrast microscopy image of a compacted tissue according to the invention in a microcompartment, taken at 4x magnification which corresponds to the schematic diagram of Figure la.
- Figure 1c are phase contrast microscopy images taken at 4x magnification of tissues compacted according to the invention in microcompartments.
- Figure 2a is a schematic representation of a sectional view of a cellular microcompartment 10, corresponding to the photo shown in Figure 2b, with an outer layer of hydrogel 12, a layer of isotonic aqueous solution 14, a layer of human cells undergoing cardiac differentiation 16 with greater thickness t2 and lesser thickness tl, and inner lumen 18.
- Figure 2b is a phase contrast microscopy image of a microcompartment taken at 4x magnification which corresponds to the schematic diagram of Figure 2a.
- Figure 3a is a schematic representation of a sectional view of a cellular microcompartment 10, corresponding to the photo shown in Figure 3b, with an outer layer of hydrogel 12, a layer of isotonic aqueous solution 14, a layer of human cells undergoing cardiac differentiation 16 with a greater thickness t2 and a lesser thickness t1, and two internal lumens 18-1 and 18-2, SI representing the thickness of the layer of isotonic aqueous solution 14.
- Figure 3b is a phase contrast microscopy image of a microcompartment taken at 4x magnification which corresponds to the schematic diagram of Figure 3a.
- Figure 3c is a phase contrast microscopy image of several microcompartments, taken at 4x magnification, each microcompartment with different morphologies.
- Figure 4a is a schematic representation of a sectional view of a cellular microcompartment 10, corresponding to the photograph shown in Figure 4b, with an outer layer of hydrogel 12, a layer of isotonic aqueous solution 14, a layer of human cells undergoing cardiac differentiation 16 with greater thickness t2 and lesser thickness t1, and two inner lumens 18-1 and 18-1, if representing the thickness of the layer of isotonic aqueous solution 14.
- Figure 4b is a phase contrast microscopy image of a microcompartment taken at 4x magnification which corresponds to the schematic diagram in Figure. 4a.
- Figure 5 includes:
- Figure 6 is includes:
- phase contrast microscopy images taken at 4x magnification.
- the image on the left shows the differentiated compacted cardiac tissues in the capsule from encapsulated hiPSCs.
- the image on the right shows the cells obtained by dissociation of cardiac tissues compacted according to the invention.
- FIG. 7 includes phase contrast microscopy images taken at 4x magnification.
- the three images in the top row (a, b and c) are images of encapsulated cells.
- the three baseline images (d, e, and f) are images of unencapsulated cells.
- the images in the left column (a and d) represent stem cells induced at the start of differentiation into cardiac cells.
- the images in the middle column (b and e) represent human cells in the process of cellular differentiation into cardiac cells, 3 to 7 days after the initiation of differentiation.
- the images of the column of right (c and f) represent differentiated cardiac tissues.
- FIG 8 is a graph which represents the percentage of cells in the tissues (obtained as in Figure 7c and 7f) expressing cardiac troponin C: on the left encapsulated tissues according to the invention (image 7c), on the right tissues not encapsulated (image 7f).
- FIG. 9 is a graph which represents the rate of cellular amplification between the start of differentiation (obtained as in Figure 7a and 7d) in the tissues: on the left according to the invention encapsulated, on the right not encapsulated.
- alginate within the meaning of the invention is meant linear polysaccharides formed from ⁇ -D-mannuronate and ⁇ -L-guluronate, salts and derivatives thereof.
- hydrogel capsule within the meaning of the invention, is meant a three-dimensional structure formed from a matrix of polymer chains, swollen with a liquid and preferably water.
- cell “expressing a gene” within the meaning of the invention is meant a cell which contains at least 5 times more copies of the RNA transcribed from the DNA sequence of the gene concerned in comparison with a pluripotent cell , preferentially 10 times more copies, preferentially 20 times more copies, preferentially 100 times more copies.
- human cells within the meaning of the invention is meant human cells or immunologically humanized non-human mammalian cells. Even when this is not specified, the cells, stem cells, progenitor cells and tissues according to the invention consist of or are obtained from human cells or from immunologically humanized non-human mammalian cells.
- progenitor cell within the meaning of the invention, is meant a stem cell already engaged in cell differentiation into cardiac cells but not yet differentiated.
- embryonic stem cell within the meaning of the invention is meant a pluripotent stem cell of a cell derived from the internal cell mass of the blastocyst.
- the pluripotency of embryonic stem cells can be assessed by the presence of markers such as the transcription factors OCT4, NANOG and SOX2 and surface markers such as SSEA3/4, Tra-1-60 and Tra-1-81.
- the embryonic stem cells used in the context of the invention are obtained without destroying the embryo from which they originate, for example using the technique described in Chang et al. (Cell Stem Cell, 2008, 2(2)): 113-117).
- human embryonic stem cells can be excluded.
- pluripotent stem cell or “pluripotent cell” within the meaning of the invention, is meant a cell which has the capacity to form all the tissues present in the entire organism of origin, without however being able to form an entire organism by as such.
- Human pluripotent stem cells may be referred to herein as hPSCs. They may in particular be induced pluripotent stem cells (iPSC or hiPSC for human induced pluripotent stem cells), embryonic stem cells or MUSE cells (for “Multilineage-differentiating Stress Enduring”).
- induced pluripotent stem cell within the meaning of the invention is meant a pluripotent stem cell induced to pluripotency by genetic reprogramming of differentiated somatic cells. These cells are notably positive for pluripotency markers, such as alkaline phosphatase staining and expression of NANOG, SOX2, OCT4 and SSEA3/4 proteins. Examples of methods for obtaining induced pluripotent stem cells are described in the articles Yu et al. (Science 2007, 318 (5858): 1917-1920), Takahashi et al (Cell, 207, 131(5): 861-872) and Nakagawa et al (Nat Biotechnol, 2008, 26(1): 101-106) .
- differentiated cardiac cells within the meaning of the invention is meant cells which exhibit the phenotype of a cardiomyocyte, that is to say expressing specific markers such as TNNC1 (cardiac troponin C gene) and ACTN2 ( alpha actinin gene) and capable of contracting spontaneously in response to an intracellular calcium signal spontaneously (in the case of immature cardiac cells) or following an electrical or chemical stimulation capable of triggering said calcium signal.
- TNNC1 cardiac troponin C gene
- ACTN2 alpha actinin gene
- differentiated cells within the meaning of the invention is meant cells which exhibit a particular phenotype, as opposed to pluripotent stem cells which are not differentiated.
- Fiber diameter of a compacted cardiac tissue according to the invention or of a microcompartment is meant the distance “d” between two tangents to said tissue compacted fabric or said microcompartment, these two tangents being parallel, such that the entire projection of said compacted fabric or said microcompartment lies between these two parallel tangents.
- variable thickness of the inner layer of human cells in the process of cell differentiation is meant within the meaning of the invention the fact that the inner layer in the same microcompartment does not have the same thickness everywhere.
- implantation or “graft” in the heart within the meaning of the invention, is meant the action of depositing at the level of the heart at a particular location at least one compacted tissue according to the invention.
- the implantation can be carried out by any means, in particular by injection.
- microcompartment or “capsule” within the meaning of the invention, is meant a partially or completely closed three-dimensional structure, containing at least one cell.
- ⁇ culture medium within the meaning of the invention is meant a culture medium animated by internal movements.
- largest dimension of a compacted cardiac tissue according to the invention or of a microcompartment within the meaning of the invention is meant the value of the largest Feret diameter of said compacted tissue or of said microcompartment.
- smallest dimension of a compacted cardiac tissue according to the invention or of a microcompartment within the meaning of the invention is meant the value of the smallest Feret diameter of said compacted tissue or of said microcompartment.
- tissue or “biological tissue” within the meaning of the invention, is meant the common sense of tissue in biology, that is to say the intermediate level of organization between the cell and the organ.
- a tissue is a set of similar cells of the same origin (usually derived from a common cell lineage, although they may find their origin by association of distinct cell lineages)., grouped into clusters, networks or bundles (fiber ).
- a tissue forms a functional whole, that is to say that its cells contribute to the same function.
- Biological tissues regenerate regularly and are assembled together to form organs.
- tissue or “compacted heart tissue” or “compacted tissue of heart cells” within the meaning of the invention, is meant a tissue unit comprising at least one heart tissue consisting at least of differentiated heart cells.
- the tissue is at least partially compacted, that is to say it is composed mainly of cells, in particular its volume is composed of more than 50% cells, preferentially 75% cells, preferentially 90% cells.
- the tissue may be completely compacted, ie the lights are no longer detectable and/or there is no light.
- the tissues compacted according to the invention can be called microtissues.
- light or “lumen” within the meaning of the invention, is meant a volume of aqueous solution topologically surrounded by cells. Preferably, its content is not in diffusive equilibrium with the volume of convective liquid present outside the microcompartment.
- the subject of the invention is therefore a compacted tissue of human cardiac cells expressing cardiac troponin C (that is to say human cells expressing the gene for cardiac troponin C, the alias of the corresponding gene being TNNC1), and preferably also alpha-actinin.
- the tissue according to the invention is therefore a human tissue comprising at least differentiated cardiac cells expressing cardiac troponin C and preferentially alpha-actinin.
- the compacted tissue according to the invention can also contain other cell types.
- the tissue has preferably been obtained, from a tissue of cardiac cells and/or of cells undergoing cardiac differentiation comprising at least one lumen, by a process comprising the compaction (so-called secondary compaction) of said tissue by total or partial disappearance of said lights.
- This compacted tissue is contractile and has a spontaneous contraction frequency of less than 4 Hz, preferably less than 2 Hz, even more preferably less than 1.7 Hz, in particular less than 1 Hz, and in particular less than 0.5 Hz.
- a spontaneous contraction frequency of less than 4 Hz, preferably less than 2 Hz, even more preferably less than 1.7 Hz, in particular less than 1 Hz, and in particular less than 0.5 Hz.
- it may be less than 0.25 Hz.
- This tissue contraction frequency is low, which is a great advantage for its implantation in the heart. Indeed, such a frequency makes it possible to avoid an arrhythmia at the time of the grafting of the compacted tissue according to the invention into the heart to be treated.
- the average human adult heart rate is between 60 and 100 beats per minute (1 to 1.7 Hz).
- the low frequency of contraction of the compacted cardiac tissues according to the invention reduces the risk of arrhythmia during a transplant of the tissues or cells obtained from these tissues. According to one embodiment, with a spontaneous beat frequency of the tissue according to the invention lower than the heart rate of the patient (recipient), this risk of arrhythmia is further reduced.
- Reduced spontaneous beat frequency is associated with the maturation of human stem cell-derived cardiomyocytes, with the 3D culture environment enhancing cardiomyocyte maturation.
- the encapsulation further reduces the contractile frequency of the compacted cardiac tissue.
- Figure 5 shows that for a given starting cell population, cardiomyocytes differentiated within a microcompartment/capsule (from encapsulated human pluripotent stem cells) have a slower spontaneous beat rate than cardiomyocytes differentiated with the same protocol. (and from the same initial batch of human pluripotent stem cells) but in free suspension culture. Thus, differentiation into cardiomyocytes from encapsulated stem cells decreases the spontaneous contractile rate.
- Human pluripotent stem cells secrete signaling molecules during the process of cardiac differentiation, which generate a specific paracrine microenvironment necessary for successful differentiation (Kempf, H. et al. Bulk cell density and Wnt/TGFbeta signaling regulate mesendodermal patterning of human pluripotent stem cells Nature Communications 7, (2016)).
- the presence of the capsule helps to increase and maintain a local concentration of these paracrine factors, which improves the differentiation phenotype, resulting in the reduction of spontaneous beat frequency.
- This tissue contraction frequency is low, which is a great advantage for its implantation in the heart. Indeed, such a frequency makes it possible to avoid an arrhythmia at the time of the grafting of the compacted tissue according to the invention into the heart to be treated.
- the compacted cardiac tissue according to the invention can remain contractile spontaneously for several months. Thus the product is stable over time.
- the cardiac tissue according to the invention has a rate of cells expressing cardiac troponin C of at least 50% in number relative to the total number of cells constituting the compacted tissue, even more preferably of at least 60%, 'at least 70%, at least 75%, at least 80%, at least 90%.
- This high rate of cells expressing cardiac troponin C is advantageous for considering uses of the cardiac tissues according to the invention in cell therapy.
- the compacted tissue of human cardiac cells according to the invention has a level of cells expressing alpha-actinin of at least 50% in number relative to the total number of cells constituting the compacted tissue, even more preferably of at least least 60%, at least 70%, at least 75%, at least 80%, and this rate may be greater than 90%.
- This high level of cells expressing alpha-actinin is advantageous for envisaging uses of the cardiac tissues according to the invention in cell therapy.
- the compacted tissue of human cardiac cells according to the invention has a rate of cells expressing troponin C and alpha-actinin of at least 50% in number relative to the total number of cells constituting the compacted tissue, even more preferably at least 60%, at least 70%, at least 75%, at least 80%, and this rate may be greater than 90%.
- This high level of cells expressing both troponin C and alpha-actinin is advantageous for envisaging uses of the cardiac tissues according to the invention in cell therapy.
- Figures 7, 8 and 9 show that for a given starting cell population, the tissues obtained within a microcompartment / capsule passing through a phase in the process of differentiation with the presence of at least one light, then a compaction secondary, presents a much higher rate of cells expressing troponin C, in comparison with tissues differentiated with the same protocol (and from the same initial batch of human pluripotent stem cells) but in culture in free suspension.
- differentiation into cardiomyocytes in microcompartments and/or by a process comprising secondary compaction makes it possible to increase the quality of cardiac tissues and therefore improves their possibility of use in cell therapy.
- the compacted cardiac tissue according to the invention can be obtained by any suitable method. According to one embodiment, it can be obtained from at least one cellular microcompartment of human cells in the process of cardiac differentiation, by a process comprising the compaction of the layer of human cells by total or partial disappearance of the light or light (s) said microcompartment.
- the fabric compacted human cardiac cells is obtained by a method as described above.
- the compacted tissue of human cardiac cells according to the invention can be totally or partially encapsulated in an outer layer of hydrogel.
- the hydrogel capsule may be the original microcompartment of human cells undergoing cardiac differentiation, or it may be a new hydrogel layer if the initial hydrogel layer has been removed , then re-encapsulation at any stage of the process.
- the encapsulation of the compacted tissue of human cardiac cells according to the invention makes it possible to protect the tissue, to maintain the frequency of spontaneous contraction below 4 Hz, preferentially below 2 Hz, even more preferentially below 1 Hz, and in particular below 0 .5 Hz and may be less than 0.25 Hz.
- the mechanism by which the contraction frequency is limited may be linked to the 3D structuring via i) the electrical continuity of the cytoplasms of cardiac cells, ii) and/or the limitation of the quantity of calcium available per cell in the intercellular space of the compacted tissues iii) and/or the mechanical resistance linked to the mechanical continuity of the cytoskeletal elements of the cardiac cells.
- the encapsulation of the cardiac compacted tissue according to the invention also makes it possible to control the size of the compacted tissue which improves the retention, the integration and the cell survival when it is injected into the heart, in particular in comparison with the injections of single cells , which increases the efficiency of cardiac cell therapy with the compacted tissues according to the invention.
- the compacted tissue of human cardiac cells according to the invention is not encapsulated in an outer hydrogel layer.
- the capsule is preferentially removed before use in order to allow the cells of the compacted tissue to implant themselves at the level of the heart after a transplant.
- the hydrogel used is biocompatible, that is to say it is not toxic to the cells.
- the outer layer of hydrogel comprises at least alginate. It may consist exclusively of alginate.
- the alginate may in particular be a sodium alginate, composed of 80% a-L-guluronate and 20%
- the outer layer is closed or partially closed.
- the compacted tissue of human cardiac cells according to the invention is preferably totally or partially surrounded by a layer of isotonic aqueous solution.
- This layer of isotonic aqueous solution is located between the packed tissue of human heart cells and the hydrogel layer when the packed heart tissue is encapsulated.
- the layer of isotonic aqueous solution preferentially contains peptide or peptidomimetic sequences capable of binding to integrins.
- isotonic aqueous solution is meant an aqueous solution having an osmolarity of between 200 and 400 mOsm/L.
- This isotonic aqueous solution preferably contains peptide or peptidomimetic sequences capable of binding to integrins. It may in particular be an extracellular matrix or a culture medium. If it is extracellular matrix, it can be constituted by extracellular matrix secreted by cells of the inner layer and/or by added extracellular matrix.
- the intermediate layer can form a gel. It preferably comprises a mixture of proteins and extracellular compounds necessary for the culture of cells undergoing cardiac differentiation.
- the aqueous solution comprises structural proteins, such as collagen, laminins, entactin, vitronectin, as well as growth factors, such as TGF-beta and/or EGF.
- the intermediate layer can consist of or comprise Matrigel® and/or Geltrex® and/or a hydrogel type matrix of vegetable origin such as modified alginates or of synthetic origin or of poly(N- isopropylacrylamide) and poly(ethylene glycol) (PNIPAAm-PEG) of the Mebiol® type.
- Matrigel® and/or Geltrex® and/or a hydrogel type matrix of vegetable origin such as modified alginates or of synthetic origin or of poly(N- isopropylacrylamide) and poly(ethylene glycol) (PNIPAAm-PEG) of the Mebiol® type.
- the extracellular matrix may optionally contain one or more cells.
- the thickness of the layer of isotonic aqueous solution around the compacted fabric according to the invention is preferably between 30 nm and 300 ⁇ m, even more preferably between 30 nm and 50 ⁇ m.
- the compacted cardiac tissue according to the invention is in three dimensions. It preferably has a spherical or elongated shape. According to a preferred embodiment, the compacted tissue of human cardiac cells has the shape of a spheroid, an ovoid, a cylinder or a sphere.
- An example of fabric compacted according to the invention is represented in FIGS. 1. In this example, the fabric compacted according to the invention is surrounded by a layer of isotonic aqueous solution and an outer layer of hydrogel.
- it has a diameter or a smaller dimension of between 10 ⁇ m and 1 mm, preferably between 100 ⁇ m and 700 ⁇ m.
- This smaller dimension is important for its survival, in particular for promoting the survival of cardiac cells within the cardiac tissue and optimizing the reorganization as well as the vascularization of the cardiac tissue after implantation in the heart.
- Its largest dimension is preferably greater than 10 ⁇ m, more preferably between 10 ⁇ m and 1 m, even more preferably between 10 ⁇ m and 50 cm. According to one embodiment, the largest dimension is compatible with the size of the organ and is therefore less than 30 cm (between 10 ⁇ m and 30 cm).
- the encapsulation of a controlled number of stem cells and/or the re-encapsulation makes it possible to control the desired size and shape of the cardiac tissues obtained.
- the size of the cardiac tissues according to the invention may vary depending on the therapeutic use envisaged.
- the compacted tissue of human cardiac cells according to the invention can be frozen, to promote its storage.
- the invention allows the production of a large number of quality human cardiac tissues by protecting the tissue units throughout their production by differentiation of pluripotent cells into cardiac cells.
- the compacted tissue of cardiac cells according to the invention can be dissociated into cells.
- the dissociation can be carried out according to conventional methods known to those skilled in the art, in particular using an enzymatic solution making it possible to separate the cells.
- the enzymes used can for example be chosen from trypsin, collagenase, accutase and mixtures thereof.
- the dissociated cells are preferably used in suspension or integrated into a gel such as a collagen gel in a patch.
- the heart tissue according to the invention can be obtained by any suitable process.
- the compacted cardiac tissue according to the invention is obtained from a microcompartment of human cells undergoing cardiac differentiation.
- It may be in particular a cellular microcompartment successively comprising, organized around at least one lumen:
- At least one inner layer of human cells in the process of cell differentiation into cardiac cells expressing at least one gene chosen from PDGFRa, MESP-1, NKX2-5, GATA4, MEF2C, TBX20, ISL1 and TBX5, (known as "internal layer "),
- intermediate layer at least one intermediate layer of isotonic aqueous solution
- outer layer at least one outer layer of hydrogel (called “outer layer”.
- the microcompartment is a three-dimensional structure therefore comprising at least one inner layer of cells. These cells are living human cells undergoing cell differentiation into cardiac cells. This layer of cells is organized in three dimensions in the microcompartment.
- the human cells in the process of cardiac differentiation present in the microcompartment are cells expressing at least one gene selected from PDGFR ⁇ , MESP-1, NKX2-5, GATA4, MEF2C, TBX20, ISL1 and TBX5. These genes are specific to cardiac cells in the process of differentiation.
- the human cells in the process of cardiac differentiation present in the microcompartment express at least two of these genes.
- human differentiating cardiac cells present in the microcompartment express all of these genes.
- the inner layer of human cells in the process of cellular differentiation into cardiac cells has a variable thickness.
- the inner layer of human cells and the lumen(s) together form a three-dimensional cellular object. If we measure the smallest and the largest thickness of the inner layer of cells along a segment passing through the geometric center of this cellular object, the ratio between the largest thickness and the smallest thickness is greater than or equal to 2.
- the inner layer thicknesses are measured along the segment passing through the geometric center of the cellular object: - at. Between :
- Figures 2, 3 and 4 represent examples of such cellular microcompartments 10, with an outer layer of hydrogel 12, a layer of isotonic aqueous solution 14, one or more internal lumen(s) 18, 18-1, 18-2, a layer of human cells in the process of cardiac differentiation 16 with a greater thickness t2 and a lesser thickness t1 (the thicknesses being measured along a segment 22 passing through the geometric center of this cellular object formed by the layer 16 and the slot(s) 18, 18-1, 18-2), the ratio t2/tl being well above 2.
- the number of human cells in the process of cell differentiation into cardiac cells of the inner layer is preferably between 1 and 100,000 cells, even more preferably between 50 and 50,000 cells, and in particular between 500 and 25,000 cells.
- Human cells in the process of cell differentiation into cardiac cells of the inner layer have preferentially been obtained from pluripotent stem cells, in particular from human pluripotent stem cells, or possibly from non-pluripotent human cells whose transcriptional profile has been modified. artificially to join that of cardiac progenitors or cardiac cells, typically by forced expression of transcription factors specific for the target cell phenotype.
- the human cells of the inner layer have been obtained from human pluripotent stem cells after contacting with a solution capable of initiating the differentiation of said stem cells.
- the intermediate layer of isotonic aqueous solution preferably contains peptide or peptidomimetic sequences capable of binding to integrins.
- isotonic aqueous solution is meant an aqueous solution having an osmolarity of between 200 and 400 mOsm/L. This layer is located between the inner cell layer and the outer hydrogel layer.
- the intermediate layer may consist of elements which have been added during the manufacture of the microcompartment and/or of elements added in the microcompartment and/or of elements secreted or induced by the other constituents of the microcompartment.
- the intermediate layer may in particular comprise or consist of an extracellular matrix and/or a culture medium. If it comprises extracellular matrix, it may be extracellular matrix secreted by cells of the inner layer and/or by extracellular matrix added at the time of preparation/manufacture of the microcompartment.
- the intermediate layer preferably comprises a mixture of proteins and extracellular compounds necessary for the culture of cells undergoing cardiac differentiation.
- the intermediate layer comprises structural proteins, such as collagen, laminins, entactin, vitronectin, as well as growth factors, such as TGF-beta and/or EGF.
- the intermediate layer can consist of or comprise Matrigel® and/or Geltrex® and/or a matrix type hydrogel of vegetable origin such as modified alginates or of synthetic origin or of copolymer of poly(N-isopropylacrylamide) and of poly(ethylene glycol) (PNIPAAm-PEG) of the Mebiol® type.
- the intermediate layer can form a gel.
- the extracellular matrix may optionally contain one or more cells.
- the thickness of the intermediate layer in the microcompartments is preferably between 30 nm and 300 ⁇ m, even more preferably between 30 nm and 50 ⁇ m.
- the presence of the intermediate layer promotes the structuring according to the invention of the elements in the microcompartment.
- the microcompartment and the inner layer of cells undergoing cardiac differentiation within the microcompartment are hollow.
- the microcompartment in fact always comprises at least one internal light or lumen which constitutes the hollow part of the microcompartment.
- the lumen contains a liquid, in particular a culture medium (such as for example an RPMI basal medium with a B27 supplement) and/or a liquid secreted by the cells of the inner layer.
- a culture medium such as for example an RPMI basal medium with a B27 supplement
- a liquid secreted by the cells of the inner layer a liquid secreted by the cells of the inner layer.
- the presence of this hollow part allows the cells to have a small diffusive volume whose composition they can control, promoting so-called autocrine/paracrine cellular communication which is in turn favorable to cardiac differentiation.
- the microcompartment can comprise several lights, at least two lights.
- This situation has the same advantage vis-à-vis autocrine and paracrine signals as the presence of a single lumen and increases the cells' ability to control the composition of the aqueous solution of the lumen because the cell to volume/cell ratio is then geometrically weaker.
- the stabilization of such a configuration demonstrates the mechanical protection offered by the microcompartment.
- the slot(s) preferably represent(s) between 10% and 90% of the volume of the microcompartment.
- the microcompartment includes an outer hydrogel layer.
- the hydrogel used is biocompatible, that is to say it is not toxic to the cells.
- the hydrogel layer must allow the diffusion of oxygen and nutrients to supply the cells contained in the microcompartment and allow their survival.
- the outer layer of hydrogel comprises at least alginate. It may consist exclusively of alginate.
- the alginate may in particular be a sodium alginate, composed of 80% a-L-guluronate and 20% pD-mannuronate, with an average molecular mass of 100 to 400 kDa and a total concentration of between 0.5 and 5% by mass.
- the hydrogel layer makes it possible to protect the cells from the external environment, to limit the uncontrolled proliferation of the cells, and their controlled differentiation into cells in the process of cardiac differentiation then into cardiac cells, at least into cardiomyocytes.
- the outer layer is closed or partially closed.
- the microcompartment is therefore closed or partially closed.
- the microcompartment is closed.
- the microcompartment can be in any three-dimensional form, that is to say it can have the shape of any object in space.
- the microcompartment is in a spherical or elongated shape. It may in particular be in the form of a hollow spheroid, a hollow ovoid, a hollow cylinder or a hollow sphere.
- the outer layer of the microcompartment i.e. the hydrogel layer, which gives the microcompartment its size and shape.
- the diameter of the smallest dimension of the microcompartment is between 10 ⁇ m and 1 mm, preferably between 100 ⁇ m and 700 ⁇ m. It may be between 10 ⁇ m and 600 ⁇ m, in particular between 10 ⁇ m and 500 ⁇ m. This smaller dimension is important for the survival of the three-dimensional cardiac tissue that will be obtained from the microcompartment, in particular to promote the survival of cardiac cells within the cardiac tissue and to optimize the reorganization as well as the vascularization of the cardiac tissue after implantation. in the heart.
- Its largest dimension is preferably greater than 10 ⁇ m, more preferably between 10 ⁇ m and 1 m, even more preferably between 10 ⁇ m and 50 cm. According to one embodiment, the largest dimension is compatible with the size of the organ and is therefore less than 30 cm (between 10 ⁇ m and 30 cm).
- the microcompartment is particularly useful for obtaining compacted cardiac tissue in three dimensions, consisting of differentiated human heart cells.
- the microcompartment can optionally be frozen for storage. It must then be thawed in order to continue the maturation of the cardiac cells and to obtain a compacted cardiac tissue according to the invention.
- the microcompartments are preferably used in series (at least two microcompartments) in a culture medium, in particular in an at least partially convective culture medium.
- the compacted cardiac tissues which are the subject of the invention are obtained from a series of cell microcompartments as described above in a closed enclosure, such as a bioreactor, preferably in a culture medium in a closed enclosure, such as a bioreactor.
- microcompartments as described above which can be used to obtain compacted cardiac tissues, can be obtained in particular by a method as described below.
- a process consists in producing cellular microcompartments comprising a hydrogel capsule surrounding:
- - differentiated cells intended to undergo in the capsule a reprogramming in the capsule so that they become induced pluripotent stem cells capable of differentiating into cardiac cells, at least into cardiomyocytes.
- the method for preparing a microcompartment may comprise at least the implementation of the steps which consist in:
- cells capable of differentiating into cardiac cells - induce cell differentiation within the cell microcompartment, so as to obtain at least a three-dimensional hollow layer of human cells in the process of cell differentiation into cardiac cells, expressing at least one gene chosen from PDGFRa, MESP-1, NKX2- 5, GATA4, MEF2C, TBX20, ISL1 and TBX5, and possibly other cells.
- the total or partial encapsulation in the hydrogel and the contribution of extracellular matrix combined is a means suitable for allowing the differentiation of human pluripotent cells towards the cardiac muscle by accumulating several advantages, in particular: i) promoting a homogeneous distribution cells of the batch within the microcompartments, ii) mechanical protection against hydrodynamic stress inflicted by the bioreactor and limitation of unwanted fusions of microcompartments, iii) organization of a microenvironment locally conserving the extracellular matrix elements promoting good survival and good cellular organization, iv) maintenance of a lumen favoring autocrine and paracrine pathways during differentiation.
- any process for the production of cellular microcompartments containing inside a hydrogel capsule at least human cells in the process of cardiac differentiation and an isotonic aqueous solution and possibly the addition of other cells, for example of support can be used.
- a suitable method is in particular described in application WO2018/096277.
- the encapsulation is carried out by co-injection of three solutions:
- an isotonic intermediate solution such as for example a sorbitol solution
- a solution comprising the cells to be encapsulated, culture medium and optionally but preferably extracellular matrix, concentrically via a microfluidic injector which makes it possible to form a jet at the injector outlet consisting of the mixture of the three solutions, said jet splitting into Tl drops, said drops being collected in a calcium bath which stiffens the hydrogel solution to form the outer layer of each microcompartment, the inner part of each drop being constituted by the solution comprising the encapsulated cells, culture medium and the extracellular matrix.
- the encapsulation is carried out with a device capable of generating hydrogel capsules using a microfluidic chip.
- the device can comprise syringe pumps for several solutions injected concentrically using a microfluidic injector which makes it possible to form a jet which splits into drops then collected in a calcium bath.
- three solutions are loaded onto three syringe pumps:
- hydrogel solution for example alginate
- an isotonic intermediate solution such as for example a sorbitol solution
- step b) the solution resulting from step b) comprising iPSCs, culture medium and optionally but preferably extracellular matrix.
- the three solutions are co-injected (injected simultaneously) in a concentric manner thanks to a microfluidic injector or microfluidic chip which makes it possible to form a jet which splits into drops whose outer layer is the hydrogel solution and the heart of the solution comprising the cells to be encapsulated; These drops are collected in a calcium bath which stiffens the alginate solution to form the shell.
- the hydrogel solution is charged with a direct current.
- a grounded ring is placed after the tip in the plane perpendicular to the axis of the jet emerging from the microfluidic injector (coextrusion chip) to generate the electric field.
- the step of producing a cellular microcompartment comprises the steps of:
- a culture medium preferably a culture medium containing the growth factors FGF2 and TGF or molecules reproducing its action on the cell, an inhibitor of the Rho kinase pathway or a molecule reproducing its action on the cell, in particular by limiting cell death.
- aqueous solution isotonic, preferably an extracellular matrix
- the encapsulated cells for the preparation of microcompartments are preferably chosen from:
- - and/or differentiated cells capable of undergoing reprogramming so that they become induced pluripotent stem cells capable of differentiating into cardiac cells, at least into cardiomyocytes.
- the encapsulated cells can be immuno-compatible with the person intended to receive the differentiated cardiac cells obtained from the microcompartment, to avoid any risk of rejection.
- the encapsulated cells have been taken beforehand from the person in whom the compacted cardiac tissues according to the invention will be implanted.
- the differentiation into cells undergoing cardiac differentiation contained in the micrococompartment can be carried out by any suitable method. This may include a method known as one of the protocols listed in (Dunn, KK & Palecek, SP Engineering Scalable Manufacturing of High-Quality Stem Cell-Derived Cardiomyocytes for Cardiac Tissue Repair. Front. Med. 5, (2018)).
- the step of inducing cell differentiation of the method comprises a step consisting in introducing capsules containing cells human strains capable of being differentiated into human cardiac cells, in a culture medium containing a WNT pathway activator (such as CHIR99021) for 12 h to 72 h, more preferably 12 to 48 hours.
- a WNT pathway activator such as CHIR99021
- the method may comprise a step which consists in incubating the microcompartments in a culture medium containing an inhibitor of the WNT pathway.
- this step is carried out between 0 and three days after the end of the differentiation induction step, preferably between 12 and 72 hours, in particular between 24 and 48 hours.
- this step consists in incubating the capsules in a culture medium containing an inhibitor of the WNT pathway, preferably for 12 hours to 48 hours, in particular between 24 to 48 hours.
- step (b) 0 to 48 hours after step (a) incubating the capsules in a culture medium containing a WNT pathway inhibitor for 24 hours to 48 hours;
- the culture medium is RPMI with B27 supplement without insulin (during the first 7 days of differentiation) and with insulin (from day 7 of differentiation).
- the microcompartments containing cells in the process of cardiac differentiation are obtained between 2 to 7 days after the start of the induction of differentiation, preferably between 3 and 7 days after the start of the induction of differentiation, even more preferably between 4 and 6 days after the start of differentiation.
- the microcompartment according to the invention appears at the time of addition of the WNT pathway inhibitor or after.
- the light is generated at the time of the formation of the layer of human cells in the process of cardiac differentiation in 3 dimensions, by the cells which multiply and develop.
- the light may contain a liquid and in particular the culture medium used for implementing the method.
- the starting stem cells organize into a three-dimensional stem cell layer around a lumen in the microcompartment, then during differentiation this lumen disappears, and a second lumen appears to form the microcompartment.
- the method is preferably implemented in a closed enclosure, such as a bioreactor, with a series of microcompartments, even more preferably in a suitable and at least partially convective culture medium.
- the method may optionally also include:
- the elimination of the capsule can be carried out in particular by hydrolysis, dissolution, piercing and/or rupture by any means that is biocompatible, that is to say non-toxic for the cells.
- removal can be achieved using phosphate buffered saline, a divalent ion chelator, an enzyme such as alginate lyase if the hydrogel includes alginate, and/or laser microdissection, and
- Reencapsulation is a suitable means for: i) optimizing the standardization of the size and the homogeneity of the compacted cardiac tissues which will then be obtained, ii) allowing an increase in the cellular amplification obtained from the pluripotent stage, and therefore a yield higher.
- the method may include a step consisting in verifying the phenotype of the cells contained in the microcompartment. This verification can be carried out by identifying the expression by at least part of the cells contained in the microcompartment, of at least one of the following genes PDGFRa, MESP-1, NKX2-5, GATA4, MEF2C, TBX20, ISL1 and TBX5.
- the method may comprise a step of freezing the microcompartments before their use to pursue differentiation into differentiated cardiac cells and to obtain compacted cardiac tissues according to the invention.
- the freezing is preferably carried out at a temperature between -190°C and -80°C. .
- Defrosting can be performed in a lukewarm water bath (preferably 37 degrees) so that the cells thaw fairly quickly.
- the microcompartments according to the invention before their use to pursue a differentiation into differentiated cardiac cells and to obtain compacted cardiac tissues can be maintained at more than 4° C. for a limited period of time before their use, preferably between 4° C. and 38° C. .
- microcompartments can also be used to pursue differentiation into differentiated cardiac cells and to obtain compacted cardiac tissues according to the invention, directly after implementation of the method, without storage and without freezing.
- cardiac differentiation within the microcompartment may be implemented and/or combined with other techniques, such as electrical stimulation and metabolic or hormonal interventions.
- Other techniques such as electrical stimulation and metabolic or hormonal interventions.
- the combination with such techniques can make it possible to further reduce the frequency of the spontaneous beats of the heart tissue compacted according to the invention before the transplant.
- the method can continue to obtain a three-dimensional object in the form of a compacted cardiac tissue according to the invention.
- the compacted cardiac tissue according to the invention can in particular be obtained from at least one cellular microcompartment of human cells in the process of cardiac differentiation as previously described, by a method comprising the compaction of the layer of human cells by total disappearance or partial of the lumen(s) of said microcompartment.
- the compacted tissue of human cardiac cells is obtained by a method as described below.
- the compacted object generally appears between 2 and 10 days after the addition of the WNT pathway inhibitor, especially between 5 and 7 days. Indeed, the addition of the inhibitor is preliminary to the compaction of the cells which continue to differentiate into cardiac cells.
- the compacted object generally appears between 7 and 14 days after the initiation of differentiation.
- the cells comprise at least in part differentiated human cardiac cells, preferably at least cardiomyocytes.
- the method may include a step of amplifying the cardiac cells in the microcompartment, and optionally one or more re-encapsulation.
- the cardiac tissue compacted according to the invention obtained can be maintained in the hydrogel capsule. Preferably, it is always surrounded by an isotonic aqueous solution, preferably an extracellular matrix.
- an isotonic aqueous solution preferably an extracellular matrix.
- the compacted fabric according to the invention is preferably stored in a capsule before use.
- the capsule containing the compacted cardiac tissue according to the invention can be frozen before removing the layer of hydrogel from the capsule.
- the method can thus comprise a step of freezing the capsules containing the compacted cardiac tissues according to the invention before their use.
- the freezing is preferably carried out at a temperature between -190°C and -80°C.
- the capsules containing the compacted cardiac tissues according to the invention before their use as a graft in the heart can be thawed in a bath of lukewarm water (preferably 37 degrees) so that the cells of the tissue thaw fairly quickly.
- the compacted cardiac tissues according to the invention can be maintained at more than 4° C. for a limited period of time before their use, preferably between 4° C. and 38° C.
- the method may comprise a step consisting in verifying the phenotype of the cells contained in the capsule. This verification can be carried out by identifying the expression of cardiac troponin C by the cardiac cells forming the compacted tissue according to the invention.
- the hydrogel layer of the capsule containing the compacted cardiac tissue according to the invention is removed.
- the elimination of the capsule can be carried out in particular by hydrolysis, dissolution, piercing and/or rupture by any means that is biocompatible, that is to say non-toxic for the cells.
- removal can be achieved using phosphate buffered saline, a divalent ion chelator, an enzyme such as alginate lyase if the hydrogel includes alginate, and/or laser microdissection.
- the elimination of the hydrogel is preferentially total, the compacted cardiac tissue according to the invention is devoid of hydrogel when it is used as a graft, implanted in a heart.
- the compacted tissue of human cardiac cells according to the invention can be used as such or else to produce a suspension of cardiac cells.
- the compacted tissue of human cardiac cells according to the invention is particularly useful for the production of a suspension of cells (graft cells) which can be implanted in the heart of a human being, in particular for the treatment of cardiac pathologies.
- the shape, size and constitution of the compacted tissue according to the invention promote homogeneous differentiation with an improved yield of cardiac cells within the compacted tissue according to the invention, which can be secondarily dissociated before implantation in the heart.
- the tissue compacted with human cardiac cells according to the invention is also particularly useful for its use as such as a graft which can be implanted in the heart of a human being, in particular for the treatment of cardiac pathologies.
- the shape, size and constitution of the compacted tissue according to the invention allow the survival of cardiac cells within the compacted tissue according to the invention, before implantation and the successful implantation, reorganization and vascularization of the graft once implanted in the heart.
- Another object of the invention is therefore the compacted tissue of human cardiac cells for its use, as such or after dissociation in the form of a suspension of cells, in therapy, in particular in cell therapy, as a medicament, in particular its use in the treatment and/or prevention of a cardiac pathology, in particular in a patient in need thereof, and preferentially in the treatment and/or prevention of an ischemic cardiac disease.
- dissociated cells obtained from the tissues according to the invention can be used, they exhibit a higher spontaneous contraction frequency than the compacted cardiac tissues.
- the slow spontaneous beating rate of differentiated cardiomyocytes within the capsule is not maintained when the cells are dissociated and cultured under 2D conditions ( Figure 6).
- Treatment means preventive, curative or symptomatic treatment, i.e. any act intended to improve a person's sight temporarily or permanently, and preferably also to eradicate the disease and/or stop or delay the disease progression and/or promote disease regression.
- the compacted tissues of human cardiac cells according to the invention can be used for the treatment of heart diseases in humans, in particular diseases having caused ischemia of at least part of the heart, such as a heart attack for example, to replace damaged areas.
- the treatment consists in implanting, grafting the compacted tissues according to the invention or the cells obtained by their dissociation in the heart, at the level of the ventricles of the hearts, in particular the left ventricle, or integrating them into a patch positioned on said ventricles , ideally between the visceral pericardium and the muscular tissue of the ventricle, or what remains of it in a pathological situation.
- a surgical implantation device suitable for implantation in the heart is very preferably used.
- These may be in particular needles, cannulas or other device making it possible to deposit the compacted tissues according to the invention or the cells obtained by dissociation of the compacted tissues according to the invention, in the heart such as for example those used for the implantation of stents in the arteries or surgical micro implants.
- the implantation can be carried out by direct myocardial injection, in particular by sternotomy or with a device based on a catheter: the compacted cardiac tissues according to the invention or the cells obtained from these tissues (with or without the addition of other cell types) are injected into the mid wall of the patient's left ventricle at one or more locations.
- the implantation can be carried out using an epicardial patch.
- the cardiac compacted tissues according to the invention or the cells obtained from these tissues (with or without the addition of other types of cells) are used in the formation of patches. These patches can then be placed on the epicardial surface of the patient's left ventricle, either by sternotomy or by a surgical procedure involving an incision and injection of the patch into the chest cavity.
- between 1 and 1,000,000 units of tissue compacted according to the invention are implanted.
- the implantation of compacted cardiac tissues according to the invention allows patients suffering from heart diseases, and in particular from ischemic heart diseases, to clinically improve cardiac function, in particular:
- the invention makes it possible to improve the overall health and the quality of life of the patient, while limiting the risk of arrhythmias induced by the transplant.
- the compacted tissues according to the invention can be useful as a model of cardiac tissue in particular:
- the invention also relates to these uses.
- FIGS. 2b and 2c are phase contrast microscopy images of a microcompartment taken at 4x magnification. They were taken 5 days after the start of differentiation (8 days after the initial encapsulation of the stem cells). The steps used to obtain the microcompartment shown in these figures are as follows:
- Encapsulated stem cells were cultured in stem cell culture media (mTeSR1) for 3 days.
- the culture medium was changed from stem cell medium to cardiac differentiation medium containing a molecule activating WNT (CHIR99021).
- the medium is RPMI medium supplemented with B27 without insulin with CHIR99021 This is considered differentiation day 0.
- the medium is RPMI medium with B27 supplement without insulin
- the medium was changed to a cardiac differentiation medium containing a molecule which inhibits the WNT pathway (C59 or IWR1).
- the medium is RPMI medium supplemented with insulin-free B27 with WNT-C59 or IWR1.
- the images in Figures 3b and 3c are phase contrast microscopy images of a microcompartment taken at 4x magnification. They were taken 5 days after the start of differentiation (11 days after the initial encapsulation of the stem cells).
- the steps used to obtain the microcompartment shown in these figures are as follows: 1. Human induced pluripotent stem cells were encapsulated in an alginate hydrogel (with extracellular matrix added at the time of encapsulation).
- Encapsulated stem cells were cultured in stem cell culture media (mTeSR1) for 6 days.
- the culture medium was changed from stem cell medium to cardiac differentiation medium containing WNT activating molecule (CHIR99021).
- the medium is RPMI medium supplemented with B27 without insulin with CHIR99021 This is considered differentiation day 0.
- the medium is RPMI medium with B27 supplement without insulin
- the medium was changed to a cardiac differentiation medium containing a molecule which inhibits the WNT pathway (C59 or IWR1).
- the medium is RPMI medium supplemented with insulin-free B27 with WNT-C59 or IWR1.
- the image in Figure 4a is a phase contrast microscopy image of a microcompartment taken at 4x magnification. It was taken 5 days after the start of differentiation (11 days after the initial stem cell encapsulation). The steps used to obtain the microcompartment shown in these figures are the same as cells to obtain Figures 3b and 3c. The difference lies in a larger number of encapsulated stem cells.
- Figure 1b and 1c are phase contrast microscopy images taken at 4x magnification of tissues compacted according to the invention in hydrogel capsules.
- the compacted tissues according to the invention were obtained by continuing the differentiation beyond day 5 (already described for the previous figures): 1.
- the culture medium was replaced by RPMI medium with B27 supplement with insulin
- the images presented in Figures 1 relate to tissues compacted > 14 days after the start of differentiation.
- FIG. 5 shows that for a given starting cell population, cardiomyocytes differentiated within the capsule (from encapsulated hiPSC) have a slower spontaneous beat rate than cardiomyocytes differentiated with the same protocol (and from the same initial batch of hiPSC) but in free-suspension culture.
- Beat frequency (defined as 1 time between spontaneous beats) was obtained from a series of phase contrast microscopy images (at a rate of at least 30 frames per second) on a tabletop microscope standard with 4x magnification. Images are phase contrast microscopy images taken at 4x magnification showing encapsulated or free-living stem cells at the start of differentiation (outermost), and final compacted tissues approximately 2 weeks after the start of differentiation (outermost). more internal).
- an intermediate step with a microcompartment according to the invention is presented on differentiation day 5.
- FIG. 6 shows that the slow spontaneous beating rate of differentiated cardiomyocytes in the capsule is slightly increased after the capsule is removed, and greatly increased after the cells have been dissociated and placed in 2D culture.
- the compacted heart tissues have a slower beat frequency than that of the isolated cells obtained by dissociation of said tissues.
- Beat frequency (defined as 1 time between spontaneous beats) was obtained from a series of phase contrast microscopy images (at a rate of at least 30 frames per second) on a tabletop microscope standard with 4x magnification.
- the beat frequency for the heart tissues compacted according to the invention encapsulated and then decapsulated was taken approximately 3 weeks after the start of differentiation.
- Figure 7 shows phase contrast microscopy images taken at 4x magnification.
- the three images in the top line (a, b and c) are images of cells encapsulated according to the invention.
- the three baseline images (d, e, and f) are images of unencapsulated cells.
- the images in the left column (a and d) represent stem cells induced at the start of differentiation into cardiac cells.
- the images in the middle column (b and e) represent human cells in the process of cellular differentiation into cardiac cells, 3 to 7 days after the initiation of differentiation.
- the images in the right column (c and f) represent differentiated cardiac tissues.
- topology is different with and without encapsulation according to the invention. Without encapsulation there is no lumen being differentiated, therefore no compaction then, and the heart tissue obtained at the end of differentiation has a very different shape.
- the cell amplification rate between the start of differentiation is greater than 2 under the conditions of the invention, whereas it is less than 0.5 for the cardiac tissues obtained under the same conditions but without encapsulation.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL301485A IL301485A (en) | 2020-09-21 | 2021-09-21 | Specific cardiac tissue and its use for the treatment of heart diseases |
CA3192855A CA3192855A1 (fr) | 2020-09-21 | 2021-09-21 | Tissu cardiaque particulier et utilisation dans le traitement de pathologies cardiaque |
AU2021344801A AU2021344801A1 (en) | 2020-09-21 | 2021-09-21 | Specific cardiac tissue and the use thereof in the treatment of cardiac pathologies |
JP2023517361A JP2023542147A (ja) | 2020-09-21 | 2021-09-21 | 特定の心臓組織及び心臓病態の治療におけるその使用 |
KR1020237013419A KR20230114742A (ko) | 2020-09-21 | 2021-09-21 | 특이적 심장 조직 및 심장 병리의 치료에서 이의 용도 |
EP21786100.4A EP4214306A1 (fr) | 2020-09-21 | 2021-09-21 | Tissu cardiaque particulier et utilisation dans le traitement de pathologies cardiaque |
CN202180071045.6A CN116529359A (zh) | 2020-09-21 | 2021-09-21 | 特定心脏组织及在心脏病理治疗中的用途 |
US18/027,209 US20230407260A1 (en) | 2020-09-21 | 2021-09-21 | Particular cardiac tissue and its use in the treatment of cardiac pathologies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2009553 | 2020-09-21 | ||
FR2009553A FR3114322A1 (fr) | 2020-09-21 | 2020-09-21 | Tissu cardiaque particulier et utilisation dans le traitement de pathologies cardiaque |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022058617A1 true WO2022058617A1 (fr) | 2022-03-24 |
Family
ID=74183270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/075951 WO2022058617A1 (fr) | 2020-09-21 | 2021-09-21 | Tissu cardiaque particulier et utilisation dans le traitement de pathologies cardiaque |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230407260A1 (fr) |
EP (1) | EP4214306A1 (fr) |
JP (1) | JP2023542147A (fr) |
KR (1) | KR20230114742A (fr) |
CN (1) | CN116529359A (fr) |
AU (1) | AU2021344801A1 (fr) |
CA (1) | CA3192855A1 (fr) |
FR (1) | FR3114322A1 (fr) |
IL (1) | IL301485A (fr) |
WO (1) | WO2022058617A1 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018096277A1 (fr) | 2016-11-23 | 2018-05-31 | Universite de Bordeaux | Microcompartiment cellulaire et procédés de préparation |
-
2020
- 2020-09-21 FR FR2009553A patent/FR3114322A1/fr active Pending
-
2021
- 2021-09-21 EP EP21786100.4A patent/EP4214306A1/fr active Pending
- 2021-09-21 IL IL301485A patent/IL301485A/en unknown
- 2021-09-21 CN CN202180071045.6A patent/CN116529359A/zh active Pending
- 2021-09-21 KR KR1020237013419A patent/KR20230114742A/ko unknown
- 2021-09-21 CA CA3192855A patent/CA3192855A1/fr active Pending
- 2021-09-21 AU AU2021344801A patent/AU2021344801A1/en active Pending
- 2021-09-21 WO PCT/EP2021/075951 patent/WO2022058617A1/fr active Application Filing
- 2021-09-21 US US18/027,209 patent/US20230407260A1/en active Pending
- 2021-09-21 JP JP2023517361A patent/JP2023542147A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018096277A1 (fr) | 2016-11-23 | 2018-05-31 | Universite de Bordeaux | Microcompartiment cellulaire et procédés de préparation |
Non-Patent Citations (42)
Title |
---|
ABECASIS BERNARDO ET AL: "Toward a Microencapsulated 3D hiPSC-Derived in vitro Cardiac Microtissue for Recapitulation of Human Heart Microenvironment Features", FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, vol. 8, 5 November 2020 (2020-11-05), XP055805304, DOI: 10.3389/fbioe.2020.580744 * |
AGARWAL PRANAY ET AL: "A Biomimetic Core-Shell Platform for Miniaturized 3D Cell and Tissue Engineering", PARTICLE AND PARTICLE SYSTEMS CHARACTERIZATION, vol. 32, no. 8, 1 August 2015 (2015-08-01), DE, pages 809 - 816, XP055805587, ISSN: 0934-0866, DOI: 10.1002/ppsc.201500025 * |
AGARWAL, P ET AL.: "A Biomimetic Core-Shell Platform for Miniaturized 3D Cell and Tissue Engineering", PART. PART. SYST. CHARACT., vol. 32, 2015, pages 809 - 816, XP055805587, DOI: 10.1002/ppsc.201500025 |
BERTERO, A.MURRY, C. E.: "Hallmarks of cardiac régénération", NAT. REV. CARDIOL., vol. 15, 2018, pages 579 - 580, XP036592889, DOI: 10.1038/s41569-018-0079-8 |
BREMBECK, F. H.ROSARIO, M.BIRCHMEIER, W: "Balancing cell adhésion and Wnt signaling, the key rôle of β-catenin", CURR. OPIN. GENET. DEV., vol. 16, 2006, pages 51 - 59, XP024959681, DOI: 10.1016/j.gde.2005.12.007 |
BURRIDGE, P. W. ET AL.: "Génération chimiquement définie de cardiomyocytes humains", NAT. METHODS, vol. 11, 2014, pages 855 - 860 |
CHANG ET AL., CELL STEM CELL, vol. 2, no. 2, 2008, pages 113 - 117 |
CHANG SAMUEL ET AL: "Emulsion-based encapsulation of pluripotent stem cells in hydrogel microspheres for cardiac differentiation", vol. 36, no. 4, 22 March 2020 (2020-03-22), XP055805792, ISSN: 8756-7938, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/btpr.2986> DOI: 10.1002/btpr.2986 * |
CHANG, S. ET AL.: "Emulsion-based Encapsulation of Pluripotent Stem Cells in Hydrogel Microspheres for Cardiac Differentiation", BIOTECHNOL. PROG., 2020 |
CHEN, K.HUANG, Y.SINGH, R.WANG, Z. Z.: "Arrhythmogenic risks of stem cell replacement therapy for cardiovascular diseases", JOURNAL OF CELLULAR PHYSIOLOGY, 2020 |
CHONG, J. J. H. ET AL.: "Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts", NATURE, vol. 510, 2014, pages 273 - 277, XP055647943, DOI: 10.1038/nature13233 |
DESGRES, M.MENASCHÉ, P.: "Clinical Translation of Pluripotent Stem Cell Therapies: Challenges and Considérations", CELL STEM CELL, vol. 25, 2019, pages 594 - 606, XP085900962, DOI: 10.1016/j.stem.2019.10.001 |
DEVALLA, H. D.PASSIER, R.: "Cardiac differentiation of pluripotent stem cells and implications for modeling the heart in health and disease", SCI. TRANSI. MED., vol. 10, 2018, pages 1 - 14 |
DUNN, KKPALECEK, SP: "Engineering fabrication évolutive de cardiomyocytes dérivés de cellules souches de haute qualité pour la réparation des tissus cardiaques", FRONT. MED., 2018, pages 5 |
HOU, D. ET AL.: "Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: Implications for current clinical trials", CIRCULATION, vol. 112, 2005, pages 150 - 156 |
ICHIMURA, H. ET AL.: "Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts", NATURE, vol. 538, 2016, pages 388 - 391 |
JIANG, B.YAN, L.SHAMUL, J. G.HAKUN, M.HE, X.: "Stem Cell Therapy of Myocardial Infarction: A Promising Opportunity in Bioengineering", ADV. THER., vol. 3, 2020, pages 1900182 |
JING DONGHUI ET AL.: "Cardiac cell génération from encapsulated embryonic stem cells in static and scalable culture systems", CELL TRANSPLANTATION, vol. 19, no. 11, 1 November 2010 (2010-11-01), pages 1397 - 1492, XP055805337, DOI: 10.3727/096368910X513955 |
JING DONGHUI ET AL: "Cardiac Cell Generation from Encapsulated Embryonic Stem Cells in Static and Scalable Culture Systems", vol. 19, no. 11, 1 November 2010 (2010-11-01), US, pages 1397 - 1412, XP055805337, ISSN: 0963-6897, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023918/pdf/nihms-264646.pdf> DOI: 10.3727/096368910X513955 * |
KADOTA, S.TANAKA, Y.SHIBA, Y: "Heart régénération using pluripotent stem cells", JOURNAL OF CARDIOLOGY, 2020 |
KEMPF, H. ET AL.: "Bulk cell density and Wnt/TGFbeta signalling regulate mesendodermal patterning of human pluripotent stem cells", NATURE COMMUNICATIONS, vol. 7, 2016 |
KERSCHER, P. ET AL.: "Direct Production of Human Cardiac Tissues by Pluripotent Stem Cell Encapsulation in Gelatin Methacryloyl", ACS BIOMATER. SCI. ENG., vol. 3, 2017, pages 1499 - 1509 |
KOIVISTO JANNE T. E: "Mechanically Biomimetic Gelatin-Gellan Gum Hydrogels for 3D Culture of Beating Human Cardiocytes", APPLIED MATERIALS & INTERFACES, vol. 11, no. 23, 12 June 2019 (2019-06-12), pages 20589 - 20602, XP055805572, DOI: 10.1021/acsami.8b22343 |
KOIVISTO JANNE T. ET AL: "Mechanically Biomimetic Gelatin-Gellan Gum Hydrogels for 3D Culture of Beating Human Cardiomyocytes", vol. 11, no. 23, 12 June 2019 (2019-06-12), US, pages 20589 - 20602, XP055805572, ISSN: 1944-8244, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsami.8b22343> DOI: 10.1021/acsami.8b22343 * |
LACO, F. ET AL.: "Selection of human induced pluripotent stem cells lines optimization of cardiomyocytes differentiation in an integrated suspension microcarrier bioreactor", STEM CELL RES. THER., vol. 11, 2020, pages 1 - 16 |
LAFLAMME, M. A.MURRY, C. E: "Heart régénération", NATURE, vol. 473, 2011, pages 326 - 335, XP037159433, DOI: 10.1038/nature10147 |
LAM, A. T. L. ET AL.: "Conjoint propagation and differentiation of human embryonic stem cells to cardiomyocytes in a defined microcarrier spinner culture", STEM CELL RES. THER., vol. 5, 2014, pages 1 - 15 |
LEE, J. H.PROTZE, S. ILAKSMAN, Z.BACKX, P. H.KELLER, G. M.: "Human Pluripotent Stem Cell-Derived Atrial and Ventricular Cardiomyocytes Develop from Distinct Mesoderm Populations", CELL STEM CELL, vol. 21, 2017, pages 179 - 194 |
LI, Q. ET AL.: "Scalable and physiologically relevant microenvironments for human pluripotent stem cell expansion and differentiation", BIOFABRICATION, vol. 10, 2018 |
LIEW, L. C.HO, B. X.SOH, B. S: "Mending a broken heart: Current stratégies and limitations of cell-based therapy", STEM CELL RES. THER., vol. 11, 2020, pages 1 - 15 |
LIU, Y.-W. ET AL.: "Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates", NATURE BIOTECHNOLOGY, vol. 36, 2018, pages 597 - 605, XP055717395, DOI: 10.1038/nbt.4162 |
MENASCHÉ, P.: "Cardiac cell therapy: Current status, challenges and perspectives", ARCHIVES OF CARDIOVASCULAR DISEASES, vol. 113, 2020, pages 285 - 292, XP086137317, DOI: 10.1016/j.acvd.2020.01.002 |
NAKAGAWA ET AL., NAT BIOTECHNOL, vol. 26, no. 1, 2008, pages 101 - 106 |
PALPANT, N. J ET AL.: "Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells", NAT. PROTOC., vol. 12, 2017, pages 15 - 31, XP037549199, DOI: 10.1038/nprot.2016.153 |
ROMAGNUOLO, R. ET AL.: "Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the Infarcted Pig Heart but Induce Ventricular Tachyarrhythmias", STEM CELL REPORTS, vol. 12, 2019, pages 967 - 981 |
TAKAHASHI ET AL., CELL, vol. 207, no. 5, pages 861 - 872 |
THOMAS, H. ET AL.: "Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prévention and Control", GLOB. HEART, vol. 13, 2018, pages 143 - 163 |
TING, S.CHEN, A.REUVENY, S.OH, S: "An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures", STEM CELL RES., vol. 13, 2014, pages 202 - 213, XP029061740, DOI: 10.1016/j.scr.2014.06.002 |
TZATZALOS, E.ABILEZ, O. J.SHUKLA, P.WU, J. C: "Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies", ADV. DRUG DELIV. REV., vol. 96, 2016, pages 234 - 244, XP029372138, DOI: 10.1016/j.addr.2015.09.010 |
YU ET AL., SCIENCE, vol. 318, no. 5858, 2007, pages 1917 - 1920 |
ZHAO SHUTING ET AL: "Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction", vol. 7, no. 1, 27 October 2016 (2016-10-27), XP055805800, Retrieved from the Internet <URL:http://www.nature.com/articles/ncomms13306> DOI: 10.1038/ncomms13306 * |
ZHAO, S. ET AL.: "Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction", NAT. COMMUN., vol. 7, 2016, pages 1 - 12, XP055805800, DOI: 10.1038/ncomms13306 |
Also Published As
Publication number | Publication date |
---|---|
JP2023542147A (ja) | 2023-10-05 |
US20230407260A1 (en) | 2023-12-21 |
AU2021344801A1 (en) | 2023-06-01 |
EP4214306A1 (fr) | 2023-07-26 |
CA3192855A1 (fr) | 2022-03-24 |
FR3114322A1 (fr) | 2022-03-25 |
KR20230114742A (ko) | 2023-08-01 |
CN116529359A (zh) | 2023-08-01 |
IL301485A (en) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4223870A1 (fr) | Microcompartiment cellulaire et procédés de préparation | |
WO2019224467A1 (fr) | Système de culture cellulaire en bioréacteur | |
CA3147254A1 (fr) | Unite tridimensionnelle creuse de tissu retinien et utilisation dans le traitement des retinopathies | |
EP4355854A1 (fr) | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes | |
WO2022058617A1 (fr) | Tissu cardiaque particulier et utilisation dans le traitement de pathologies cardiaque | |
EP4214305A1 (fr) | Microcompartiments cellulaires comprenant des cellules humaines en cours de differenciation cardiaque, tissus obtenus a partir de ces microcompartiments et utilisations | |
WO2022238485A1 (fr) | Microcompartiments cellulaires comprenant des cellules dont l'intégrité génomique est maintenue apres amplification et procede de preparation | |
Dessauge et al. | Développement des modèles de culture cellulaire de muscle en 3D: de nouvelles opportunités pour les productions animales | |
FR3124193A3 (fr) | Microcompartiments cellulaires de grande taille comprenant plusieurs cystes | |
WO2023214055A1 (fr) | Microtissu hepatique particulier en trois dimensions et utilisations dans le traitement de l'insuffisance hepathique | |
WO2024033284A1 (fr) | Substitut de matrice extracellulaire dans un microcompartiment cellulaire | |
FR3138661A1 (fr) | Substitut de matrice extracellulaire dans un microcompartiment cellulaire | |
FR2807765A1 (fr) | Procede de culture de cellules, amas cellulaires obtenus par ces procedes et utilisation de ceux-ci | |
FR3135278A1 (fr) | Microtissu hépatique particulier et utilisations dans le traitement de l’insuffisance hépatique | |
FR3135279A1 (fr) | Microtissu hépatique particulier et utilisations dans le traitement de l’insuffisance hépatique | |
Wang | CHARACTERIZING PHYSIOCHEMICAL PROPERTIES OF DIFFERENTIALLY TUNED HYDROGELS, AND INVESTIGATING BEHAVIOR AND FUNCTION OF CELLS WITHIN | |
FR3134117A1 (fr) | Microcompartiments cellulaires comprenant des lymphocytes adaptés pour la culture à grande échelle | |
Bose et al. | Cell Therapy for Diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21786100 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023517361 Country of ref document: JP Kind code of ref document: A Ref document number: 3192855 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180071045.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021786100 Country of ref document: EP Effective date: 20230421 |
|
ENP | Entry into the national phase |
Ref document number: 2021344801 Country of ref document: AU Date of ref document: 20210921 Kind code of ref document: A |